Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6798623 | 0.83 | CYP3A4 (0.32) | CYP3A4ALOX5KDM4E | |
| SCHEMBL1954826 | 0.81 | SIGMAR1 (0.44) | SIGMAR1LMNACYP3A4TRPM8TSHR | |
| SCHEMBL6804244 | 0.80 | PTPN1 (0.43) | KDM4EHPGDALDH1A1 | |
| SCHEMBL6796726 | 0.79 | BCAT2 (0.40) | LMNAALOX5HPGDALDH1A1 | |
| SCHEMBL6798273 | 0.79 | SIGMAR1 (0.42) | SIGMAR1ALOX5KDM4EALDH1A1 | |
| SCHEMBL1416436 | 0.77 | NPSR1 (0.45) | LMNACYP3A4TRPM8TSHRNPSR1 | |
| SCHEMBL6792417 | 0.77 | PLAU (0.38) | SIGMAR1LMNAKDM4EALDH1A1 | |
| SCHEMBL5994911 | 0.76 | SIGMAR1 (0.36) | SIGMAR1LMNACYP3A4TRPM8TSHR | |
| SCHEMBL11412194 | 0.75 | SIGMAR1 (0.33) | SIGMAR1LMNACYP3A4TRPM8TSHR | |
| SCHEMBL27556184 | 0.74 | MAPT (0.35) | LMNACYP3A4TSHRALOX5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0917462-B1 | CELL ADHESION INHIBITORS | BIOGEN IDEC INC (US) | 2006-09-13 | — | — | EP | disclosed |
| US-20060030553-A1 | Cell adhesion inhibitors | ZHENG ZHONGLI | 2006-02-09 | — | — | US | disclosed |
| US-6949534-B2 | Cell adhesion inhibitors | BIOGEN IDEC MA INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040053907-A1 | Cell adhesion inhibitors | BIOGEN, INC. A MASSACHUSETTS CORPORATION. | 2004-03-18 | — | — | US | disclosed |
| US-6686350-B1 | Cell adhesion inhibitors | BIOGEN, INC. | 2004-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053907-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | SIGMAR1 4304/4885LMNA 2271/4885CYP3A4 4841/4885 |
| US-20060030553-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | SIGMAR1 4304/4885LMNA 2271/4885CYP3A4 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.